FDA's research is "central to our understanding of BPA"

The Food and Drug Administration's science-based research on bisphenol A is groundbreaking and finally gaining acknowledgement from some anti-BPA activists, writes Trevor Butterworth, who interviews Daniel Doerge of the FDA. The FDA's research is finding that "internal exposures to active BPA, whether in the mother or in the fetus, are orders of magnitude lower than those in most so-called 'low dose' studies claiming adverse effects," Butterworth writes.

View Full Article in:

Forbes · Gazette (Montreal) (tiered subscription model), The

Published in Brief: